Rheumatoid Arthritis

Elderly Patients Underrepresented in Clinical Trials for Rheumatoid Arthritis, Osteoarthritis

Elderly Patients Underrepresented in Clinical Trials for Rheumatoid Arthritis, Osteoarthritis

By

Data show that the elderly are underrepresented in randomized clinical trials for rheumatoid arthritis and osteoarthritis.

Improving RA Diagnosis With Use of Anti-ACPAs

Improving RA Diagnosis With Use of Anti-ACPAs

By

In patients with rheumatoid arthritis, the use of multiple antibody assays may improve clinical diagnosis and disease management.

Ultrasound May Be Reliable for Assessing Subtalar Joint Synovitis in Rheumatoid Arthritis

Ultrasound May Be Reliable for Assessing Subtalar Joint Synovitis in Rheumatoid Arthritis

By

Data show that ultrasound is a reliable means of evaluating subtalar joint synovitis in patients with rheumatoid arthritis.

Bone Erosions More Frequent With Old Age at Onset of Early RA

Bone Erosions More Frequent With Old Age at Onset of Early RA

Old age at onset of early rheumatoid arthritis is associated with more frequent bone erosions.

Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?

Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?

By

Recent research points to an association between the gut microbiome composition and various types of immune-mediated inflammatory arthritides.

Single-Dose Prefilled Autoinjector for Actemra Approved

Single-Dose Prefilled Autoinjector for Actemra Approved

By

Genentech announced that the FDA has approved ACTPen autoinjector for Actemra as a new formulation for adults with moderate to severe active RA.

Functional Disability Progression More Rapid in Postmenopausal Women With RA

Functional Disability Progression More Rapid in Postmenopausal Women With RA

By

Functional disability progressed more rapidly in postmenopausal compared with premenopausal women with rheumatoid arthritis.

Physician-Patient Discordance of Global Assessment Higher in Osteoarthritis vs Rheumatoid Arthritis

Physician-Patient Discordance of Global Assessment Higher in Osteoarthritis vs Rheumatoid Arthritis

By

Researchers compared patient-physician discordance in global assessment in patients with osteoarthritis vs patients with rheumatoid arthritis seen in routine care.

Rituximab Biosimilar Shows Similar Safety to Reference Biologic in RA

Rituximab Biosimilar Shows Similar Safety to Reference Biologic in RA

By

The safety of switching from reference rituximab to the rituximab biosimilar was comparable to continuation of reference rituximab.

Factors Affecting Hand Function, Disability in Rheumatoid Arthritis

Factors Affecting Hand Function, Disability in Rheumatoid Arthritis

By

Data highlight a lack of consideration of personal and environmental factors when studying the effects of RA on hand function.

Autoimmune Thyroid Disease Associated With Onset of Rheumatoid Arthritis

Autoimmune Thyroid Disease Associated With Onset of Rheumatoid Arthritis

By

Rheumatoid arthritis is associated with an increased occurrence of autoimmune thyroid disease, indicated by an increased risk of developing autoimmune thyroid disease before RA diagnosis.

Risk for Peripheral Neuropathy Assessed in Patients With Rheumatic Diseases

Risk for Peripheral Neuropathy Assessed in Patients With Rheumatic Diseases

By

Researchers assessed the risk for peripheral neuropathy with TNFi in patients with rheumatic diseases.

Biosimilar Hyrimoz Gains FDA Approval

Biosimilar Hyrimoz Gains FDA Approval

By

The FDA's approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product's safety, efficacy, and quality.

Influenza Vaccination Low in Rheumatoid Arthritis, Psoriatic Arthritis

Influenza Vaccination Low in Rheumatoid Arthritis, Psoriatic Arthritis

By

Patients with rheumatoid arthritis or psoriatic arthritis have a low influenza vaccination rate, despite the recommendation from the CDC to be vaccinated annually.

Novel JAK Inhibitor Peficitinib Effective, Tolerable in Treating Rheumatoid Arthritis

Novel JAK Inhibitor Peficitinib Effective, Tolerable in Treating Rheumatoid Arthritis

By

Peficitinib significantly reduced symptoms in patients with rheumatoid arthritis and demonstrated tolerability and safety.

JAK Inhibitors, Biologic DMARDs Yield Better Quality of Life Outcomes in Rheumatoid Arthritis

JAK Inhibitors, Biologic DMARDs Yield Better Quality of Life Outcomes in Rheumatoid Arthritis

By

JAK inhibitors and biologic DMARDs demonstrated better SF-36 Physical Component Summary and Mental Component Summary scores at 12 weeks.

Validating Clinical Risk Score of NSAID Toxicity in Osteoarthritis, RA

Validating Clinical Risk Score of NSAID Toxicity in Osteoarthritis, RA

By

Data from the PRECISION trial were used to develop and validate a clinical risk score for NSAID toxicity in OA and RA.

Physical Activity May Prevent Increased Cognitive Dysfunction in RA

Physical Activity May Prevent Increased Cognitive Dysfunction in RA

By

Meeting the US Department of Health and Human Services guidelines for physical activity appears to be protective against worsening concentration and word retrieval in patients with rheumatoid arthritis.

Predictors of Persistent Disease Activity During First Year of RA Treatment

Predictors of Persistent Disease Activity During First Year of RA Treatment

By

Researchers examined predictors of persistent disease activity during the first year of rheumatoid arthritis treatment in men and women.

Geographic, Clinical Factors of Triple Therapy Initiation in Rheumatoid Arthritis

Geographic, Clinical Factors of Triple Therapy Initiation in Rheumatoid Arthritis

By

The use of triple therapy is infrequent in patients with rheumatoid arthritis in the United States.

Updated Baricitinib Safety Data Available for Active Rheumatoid Arthritis

Updated Baricitinib Safety Data Available for Active Rheumatoid Arthritis

Terence Rooney, MD, senior medical director, Lilly Bio-Medicines, discusses updated baricitinib safety data presented at ACR/ARHP 2018.

Positive Phase 3 Results With Filgotinib for Treatment-Resistant Rheumatoid Arthritis

Positive Phase 3 Results With Filgotinib for Treatment-Resistant Rheumatoid Arthritis

By

Treatment with filgotinib over 24 weeks resulted in significant improvements in the signs and symptoms of RA among patients with inadequate response or intolerance to biologic DMARDs.

CVD Risk Reduced in Rheumatoid Arthritis Treated With Methotrexate and bDMARDs

CVD Risk Reduced in Rheumatoid Arthritis Treated With Methotrexate and bDMARDs

By

A reduction in CVD risk was found with concomitant methotrexate and bDMARD use for rheumatoid arthritis.

VTE Risk in RA Not Significantly Higher With Tofacitinib vs TNF Inhibitors

VTE Risk in RA Not Significantly Higher With Tofacitinib vs TNF Inhibitors

By

Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.

Similar Long-Term Efficacy for Infliximab Biosimilar, Reference Product in RA

Similar Long-Term Efficacy for Infliximab Biosimilar, Reference Product in RA

By

The efficacy, safety, and immunogenicity of the infliximab biosimilar and the infliximab reference product were comparable from 54 to 78 weeks.

Obesity Negatively Affects Treatment Response to JAK Inhibitors in RA

Obesity Negatively Affects Treatment Response to JAK Inhibitors in RA

By

Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.

Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis

Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis

By

Abatacept reduced the risk for diabetes in patients with rheumatoid arthritis.

High-Dose Trivalent Inactivated Influenza Vaccine Improves Seroconversion Rate in RA

High-Dose Trivalent Inactivated Influenza Vaccine Improves Seroconversion Rate in RA

By

A high-dose trivalent vaccine may enhance antibody production against influenza in people with RA.

Upadacitinib Demonstrates Superiority vs Adalimumab, Placebo in Treatment-Resistant RA

Upadacitinib Demonstrates Superiority vs Adalimumab, Placebo in Treatment-Resistant RA

By

Upadacitinib resulted in greater improvements in rheumatoid arthritis signs and symptoms compared with placebo and adalimumab.

Real-Time Feedback on Treatment Satisfaction May Improve Treat-to-Target Approach in RA

Real-Time Feedback on Treatment Satisfaction May Improve Treat-to-Target Approach in RA

By

Real-time patient input about treatment satisfaction can improve management strategies in patients with rheumatoid arthritis.

Sign Up for Free e-newsletters